Sterling Capital Management LLC Has $30.56 Million Holdings in DexCom, Inc. $DXCM

Sterling Capital Management LLC grew its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 36.4% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 350,140 shares of the medical device company’s stock after acquiring an additional 93,526 shares during the period. Sterling Capital Management LLC’s holdings in DexCom were worth $30,564,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in DXCM. Vanguard Group Inc. lifted its stake in shares of DexCom by 2.0% in the 1st quarter. Vanguard Group Inc. now owns 47,455,899 shares of the medical device company’s stock valued at $3,240,763,000 after purchasing an additional 925,882 shares during the last quarter. Jennison Associates LLC lifted its position in shares of DexCom by 9.4% in the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after buying an additional 994,300 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of DexCom by 22.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock worth $691,336,000 after acquiring an additional 1,868,241 shares in the last quarter. Nuveen LLC acquired a new position in shares of DexCom during the 1st quarter valued at about $554,893,000. Finally, Raymond James Financial Inc. raised its stake in shares of DexCom by 21.8% in the 1st quarter. Raymond James Financial Inc. now owns 3,355,057 shares of the medical device company’s stock valued at $229,117,000 after acquiring an additional 601,088 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the company. Piper Sandler set a $75.00 price target on DexCom and gave the company a “buy” rating in a report on Friday, October 31st. Oppenheimer downgraded shares of DexCom from an “outperform” rating to a “market perform” rating in a report on Monday, September 8th. BTIG Research decreased their price target on shares of DexCom from $109.00 to $85.00 and set a “buy” rating for the company in a report on Friday, October 31st. Wells Fargo & Company set a $93.00 price objective on DexCom and gave the stock an “overweight” rating in a research note on Friday, October 31st. Finally, Morgan Stanley increased their target price on DexCom from $82.00 to $89.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and a consensus price target of $89.33.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 500 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the transaction, the executive vice president directly owned 94,102 shares in the company, valued at $7,555,449.58. This represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Kyle Malady sold 667 shares of the company’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the completion of the sale, the director directly owned 22,667 shares in the company, valued at approximately $1,832,853.62. The trade was a 2.86% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 5,383 shares of company stock valued at $434,274. 0.32% of the stock is currently owned by company insiders.

DexCom Trading Down 2.1%

Shares of DexCom stock opened at $58.02 on Friday. DexCom, Inc. has a 52-week low of $56.44 and a 52-week high of $93.25. The firm has a market capitalization of $22.63 billion, a PE ratio of 40.29, a price-to-earnings-growth ratio of 1.43 and a beta of 1.40. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The company’s fifty day moving average price is $69.65 and its two-hundred day moving average price is $77.65.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.04. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm’s revenue was up 21.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.45 EPS. DexCom has set its FY 2025 guidance at EPS. On average, analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.